Combination drugs to wake up hidden HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV-1 (subtype A, B, C, or D) and are 18 or older.
- You've been on HIV medication without missing more than 2 days a month for at least 6 months.
- Your viral load has been undetectable (below 50 copies/mL) for at least 3 months.
- Your current CD4 count is 200 or higher.
- You do not have active hepatitis B or C, active cancer, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.